Page title

Practitioner and Program Data

Bupe info graphic

Learn how SAMHSA evaluates the buprenorphine waiver program under the Drug Addiction Treatment Act of 2000 (DATA 2000) and tracks the number of DATA-waived practitioners.

Cumulative DATA-Waivered Certified Practitioners by Waiver Limit as of November 27, 2022


Data Updated Daily

Bupe widget

Main page content

Since October 2002 when the Food and Drug Administration (FDA) approved buprenorphine for clinical use in treating opioid dependency, SAMHSA has worked with practitioners to help them obtain waivers to meet the requirements of the Drug Addiction Treatment Act of 2000 (DATA 2000). DATA 2000 sets eligibility and certification requirements as well as an interagency notification review process for practitioners who apply.

In conjunction with these efforts, SAMHSA tracks the number of practitioner waivers held throughout the country and monitors the progress of the program as a whole to evaluate its effectiveness.

Number of DATA-Waived Practitioners

SAMHSA uses the Notice of Intent (NOI) to implement the provisions of DATA 2000 and the SUPPORT Act that permit practitioners to prescribe or dispense buprenorphine. The form is used to collect all of the necessary information from practitioners to determine if they meet specific qualifications. This information is also used to track the number of DATA-waived practitioners by state who are eligible to treat up to 30, up to 100, or up to 275 patients at a time.

Evaluation of the Buprenorphine Waiver Program

Results from a 2005 congressionally mandated evaluation study show how DATA 2000 has expanded opioid-assisted treatment. The study presents practitioner and patient survey results on treatment outcomes, patient characteristics, prescribing trends, barriers to treatment, and other information.

Overall, the study found that:

  • The waiver program appears to have increased the availability of medication-assisted treatment (MAT) for opioid dependency
  • Treatment provided under the wavier program has been safe and effective
  • Diversion, adverse clinical events, and public health consequences under the program have been minimal
  • The 30-patient limit on individual practitioner practices, as well as continuing cost and reimbursement issues, have dampened the full potential of buprenorphine to improve access

Evaluation Findings and Presentations

Learn more about SAMHSA’s buprenorphine waiver management program.

Last Updated

Last Updated: 08/19/2022